Cochlear's Osia 3 clears FDA on a 29-patient satisfaction result
The SONUS trial backing Cochlear's newest bone conduction processor reported 97% patient satisfaction with sound quality, but disclosed no comparative outcome, safety, or endpoint data against the Osia 2.
Executive Summary
- Cochlear secured FDA clearance for its newest bone conduction sound processor, the direct successor to a device already used by tens of thousands of patients.
- The clinical data backing the launch is a patient satisfaction figure from a small study, not a comparative hearing-performance result against the prior generation.
- The study compares the new processor to its immediate predecessor, so the relevant question is whether hearing outcomes held steady or improved, not whether a new mechanism works.
- The disclosed metric captures how patients felt about sound quality, leaving the underlying speech-understanding and audiometric comparisons still to be shown.
The announcement
Cochlear Limited said on July 13, 2026 that the FDA cleared its new Osia 3 Sound Processor, an active bone conduction hearing device for conductive hearing loss, mixed hearing loss and single-sided deafness. The company positioned the device as the first fully rechargeable processor in its class, offering up to 30 hours of battery life and an updated signal-processing chip built for wider frequency bandwidth. It succeeds the Osia 2, which the company said tens of thousands of patients already use. CochlearCochlear introduces the new Osia® 3 Sound ProcessorJul 13, 2026
The clinical result
The clearance announcement cited results from the SONUS study, registered as NCT07156461, which compared the Osia 3 against the Osia 2 Sound Processor in adult Osia implant recipients. Cochlear reported that 97% of the 29 patients analyzed in the study were satisfied or very satisfied with the Osia 3's overall sound quality. The press release also said patients demonstrated improved speech understanding and preferred the new device's sound quality over the prior generation, though it did not disclose the size of that difference. NCT07156461+1NCT07156461Cochlear introduces the new Osia® 3 Sound ProcessorJul 13, 2026
How it was done
The registry record shows the trial moved from not-yet-recruiting to recruiting on September 22, 2025 and reached completed status on January 8, 2026, a roughly four-month enrollment-to-completion window for the 29-patient cohort. No results have been posted to the trial's own ClinicalTrials.gov results record as of this writing. The one figure Cochlear disclosed publicly, the 97% satisfaction rate, is a patient-reported measure; it does not by itself establish a comparative audiometric or speech-recognition advantage over the Osia 2. NCT07156461
The stake
Because the Osia 2 is already an approved, widely used device, the relevant bar for the Osia 3 is replication of its established hearing-outcome profile alongside the disclosed hardware upgrades, rather than a new efficacy hurdle. Cochlear's own portfolio includes 53 completed trials against 8 terminated and 2 withdrawn studies across its history, a pattern consistent with a device maker running frequent, small confirmatory studies alongside product iterations rather than large pivotal efficacy trials.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.